Rockefeller Capital Management
TBPH icon

Rockefeller Capital Management’s Theravance Biopharma TBPH Stock Holding History

Rockefeller Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.63K Sell
449
-501
-53% -$8.29K ﹤0.01% 4112
2026
Q1 		$15.4K Buy
950
+709
+294% +$12.5K ﹤0.01% 3816
2025
Q4 		$4.51K Buy
241
+190
+373% +$3.15K ﹤0.01% 4105
2025
Q3 		$745 Buy
+51
New +$644 ﹤0.01% 4223
2022
Q1 		– Sell
-625
Closed -$6K – 4058
2021
Q4 		$6K Buy
+625
New +$5.45K ﹤0.01% 3216

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Rockefeller Capital Management's TBPH Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Theravance Biopharma (TBPH) stake by 53% in Q2 2026, selling an estimated $8.29K and leaving 449 shares worth $7.63K. The position accounts for ﹤0.01% of the portfolio, ranked #4112.

Rockefeller Capital Management first reported a position in TBPH in Q4 2021 and has held it in 5 quarters since. The position peaked at $15.4K in Q1 2026. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Rockefeller Capital Management held 449 shares of Theravance Biopharma worth $7.63K as of Q2 2026.
  • Rockefeller Capital Management sold 501 Theravance Biopharma shares in Q2 2026, an estimated $8.29K.
  • Theravance Biopharma made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4112 holding.
  • Rockefeller Capital Management first reported a position in Theravance Biopharma in Q4 2021 and has held it in 5 quarters since.
  • Rockefeller Capital Management's Theravance Biopharma position peaked at $15.4K in Q1 2026.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.